文献速递肝病

MELD仍是肝硬化伴严重腹水门诊患者死亡的最佳预测指标

MELD remains the best predictor of mortality in outpatients with cirrhosis and severe ascites.
PubMed 文献 · Aliment Pharmacol Ther · 2020-06-23

该研究利用随机试验SPARe-1中肝硬化伴严重腹水患者的数据,尝试开发优于MELD评分的1年死亡预测模型。最终模型(SAM评分)纳入血清胆红素、血清钠、自发性细菌性腹膜炎病史和糖尿病,校正乐观偏倚后其预测能力与MELD几乎相同。外部验证队列中MELD评分略优,研究未能开发出优于MELD的预测模型。

要点

  • 在肝硬化伴严重腹水且MELD≤18的患者中,MELD仍是1年死亡的最佳预测指标。
  • 新开发的SAM评分包含胆红素、钠、自发性细菌性腹膜炎病史和糖尿病四个变量。
  • SAM评分与MELD评分预测能力几乎相同,未能超越MELD。

核心结论

  • 研究未能开发出在肝硬化伴严重腹水患者中优于MELD评分的预测模型。

研究设计与样本

  • 利用随机试验SPARe-1中肝硬化伴严重腹水患者的数据开发预测1年死亡的模型,采用逐步后退消除法和Cox回归识别最强预测因子,用C指数和Brier评分评估性能,并在SPARe-2试验参与者外部队列中验证。

主要发现

  • 开发队列纳入308例患者,1年死亡率为20.4%。
  • 最终预测模型(严重腹水死亡评分,SAM评分)包含四个变量:血清胆红素、血清钠、自发性细菌性腹膜炎病史(是或否)和糖尿病(是或否)。
  • 校正乐观偏倚后,SAM评分与MELD评分的预测能力几乎相同。
  • 外部验证队列纳入149例患者,1年死亡率为22.4%,MELD评分在该队列中表现略好,部分因为自发性细菌性腹膜炎和糖尿病对死亡率的影响在该队列中要小得多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Model for Endstage Liver Disease (MELD) score may put patients with severe ascites at a disadvantage because they often have a poor quality of life and high mortality despite a favourable MELD score. AIM: To develop a model that is better than the MELD score at predicting 1-year mortality among patients with cirrhosis, severe ascites and MELD ≤18. METHODS: We used data from a randomised trial (SPARe-1) of patients with cirrhosis and severe ascites to develop a model to predict 1-year mortality. We used stepwise backward elimination and Cox regression to identify the strongest predictors. Performance was assessed with the C index and the Brier score. We examined performance in an external cohort of trial participants with cirrhosis and severe ascites (SPARe-2 participants). RESULTS: We included 308 patients with a 1-year mortality of 20.4%. The final prediction model (Severe Ascites Mortality score, "SAM score") included four variables: serum bilirubin, serum sodium, history of SBP (yes or no) and diabetes (yes or no). No indicators of quality of life were included. After correction for optimism bias, the SAM and MELD scores had nearly identical predictive ability. The external validation cohort included 149 patients whose 1-year mortality was 22.4%. The MELD score performed marginally better in this cohort, partly because the effects of SBP and diabetes on mortality were much smaller in this cohort. CONCLUSION: We did not succeed in developing a prediction model that was superior to the MELD score among patients with cirrhosis and severe ascites.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jepsen P, Watson H, Macdonald S, et al. MELD remains the best predictor of mortality in outpatients with cirrhosis and severe ascites. Aliment Pharmacol Ther. 2020. PMID: 32573818. doi:10.1111/apt.15882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。